Palatin Technologies, Inc. (PTN)
After hours:
| Previous close | 1.7900 |
| Open | 1.7900 |
| Bid | 1.8400 x 1000 |
| Ask | 1.8500 x 800 |
| Day's range | 1.8050 - 1.9300 |
| 52-week range | 1.4300 - 5.6500 |
| Volume | |
| Avg. volume | 661,967 |
| Market cap | 29.691M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9800 |
| Earnings date | 14 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.33 |
PR NewswirePalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET. To register, click here.
Insider Monkey10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
ZacksPalatin (PTN) Up 15% on Results From Dry Eye Disease Study
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
